Our mission is to conduct effective advocacy for public policies that encourage the discovery of important, new medicines for patients by biopharmaceutical research companies. To accomplish this mission, we are dedicated to achieving these goals in Washington, D.C. and across the country.

Featured Blogs

With the first list of medicines out, let’s not forget why government price setting is bad policy

Nicole Longo
CMS had the potential to mitigate some of the harms of the price setting program when it finalized its guidance earlier this summer, but the agency failed to do so.

New analysis shows PBMs use fees as a profit center

Stephen J. Ubl
Pharmacy benefit managers (PBMs) demand more than double the amount of fees today than they did five years ago, according to a new report from Nephron Research.

340B program reaches $100 billion in sales, while patients are left behind

Nicole Longo
The 340B Drug Pricing Program has grown yet again, exceeding $100 billion in sales in 2022 when 340B-priced medicines are measured at wholesale acquisition cost.

This website uses cookies and other tracking technologies to optimize performance, preferences, usage, and statistics. By clicking “Accept All”, you consent to store on your device the cookies and other tracking technologies that require consent. You can tailor or change your preferences by clicking “Manage My Cookies”. You can check our privacy policy for more information.